Sign Out
Decitabine is indicated for: the treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System (IPSS) groups; the treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukemia (AML), according to the World Health Organization (WHO) classification who are not candidates for standard induction chemotherapy.
The efficacy of decitabine has not been fully reported in patients under the age of 65 years.
Continue with Google